Pedro Miguel dos Santos Abrantes

Pedro Miguel dos Santos Abrantes

Auto-generated profile, based on publicly available information

Pedro Miguel dos Santos Abrantes

Maternal Endogenous Infections Studies (MEnIS) Research Laboratories, Department of Medical Biosciences, University of the Western Cape, Bellville, South Africa

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
PAPedro Miguel dos Santos Abrantes
Pedro Miguel dos Santos Abrantes
CMCarole McArthur
Carole McArthur
CACharlene Africa
Charlene Africa


20 January 2017 in F1000Research
Verified
Journal Article
Open access
PDF file
CACharlene Africa
Charlene Africa
PAPedro Miguel dos Santos Abrantes
Pedro Miguel dos Santos Abrantes
Background:Candidainfections are responsible for increased morbidity and mortality rates in at-risk patients, especially in developing countries where there is limited access to antifungal drugs and a high burden of HIV co-infection. Objectives:This study aimed to identify antifungal drug resistance patterns within the subcontinent of Africa. Methods: A literature search was conducted on published studies that employed antifungal susceptibility testing on clinicalCandidaisolates from sub-Saharan African countries using Pubmed and Google Scholar. Results: A total of 21 studies from 8 countries constituted this review. Only studies conducted in sub-Saharan Africa and employing antifungal drug susceptibility testing were included. Regional differences inCandidaspecies prevalence and resistance patterns were identified. Discussion: The outcomes of this review highlight the need for a revision of antifungal therapy guidelines in regions most affected byCandidadrug resistance. Better controls in antimicrobial drug distribution and the implementation of regional antimicrobial susceptibility surveillance programmes are required in order to reduce the highCandidadrug resistance levels seen to be emerging in sub-Saharan Africa.

8 December 2016 in F1000Research
Verified
Journal Article
Open access
PDF file
CACharlene Africa
Charlene Africa
PAPedro Miguel dos Santos Abrantes
Pedro Miguel dos Santos Abrantes
Background:Candidainfections are responsible for increased morbidity and mortality rates in at-risk patients, especially in developing countries where there is limited access to antifungal drugs and a high burden of HIV co-infection. Objectives:This study aimed to identify antifungal drug resistance patterns within the subcontinent of Africa. Methods: A literature search was conducted on published studies that employed antifungal susceptibility testing on clinicalCandidaisolates from sub-Saharan African countries using Pubmed and Google Scholar. Results: A total of 21 studies from 8 countries constituted this review. Only studies conducted in sub-Saharan Africa and employing antifungal drug susceptibility testing were included. Regional differences inCandidaspecies prevalence and resistance patterns were identified. Discussion: The outcomes of this review highlight the need for a revision of antifungal therapy guidelines in regions most affected byCandidadrug resistance. Better controls in antimicrobial drug distribution and the implementation of regional antimicrobial susceptibility surveillance programmes are required in order to reduce the highCandidadrug resistance levels seen to be emerging in sub-Saharan Africa.

1 March 2022 in Journal of Herbal Medicine
Verified
Journal Article
Closed access
TNTiza L. Ng’uNi
Tiza L. Ng’uNi
PAPedro Miguel dos Santos Abrantes
Pedro Miguel dos Santos Abrantes
CMCarole McArthur
Carole McArthur
JKJEREMY KLAASEN
JEREMY KLAASEN
BFBurtram C. Fielding
Burtram C. Fielding

24 May 2019 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
CJCathy N. John
Cathy N. John
PAPedro M. D. S. Abrantes
Pedro M. D. S. Abrantes
BPBhupesh K. Prusty
Bhupesh K. Prusty
DADharam V. Ablashi
Dharam V. Ablashi
CACharlene Africa
Charlene Africa
Background/Objectives: With mucocutaneous candidiasis being highly prevalent in HIV patients, the emergence of fluconazole-resistant Candida species forms a major challenge in treating and eradicating these infections. The objective of this study was to establish the antifungal activity of K21, a membrane-rupturing antimicrobial compound derived from a silica quaternary ammonium compound (SiQAC) with tetraethoxysilane (TEOS). Methods: The study sample included 81 Candida species of which 9 were type strains and 72 were clinical isolates. Minimum inhibitory concentrations, synergy, fractional inhibitory concentration index (FICI), and time kill assays were determined by broth microdilution. Electron microscopy (EM) was used to determine the qualitative changes brought about after treatment with K21. Results: K21 inhibited the growth of all fluconazole-resistant and susceptible Candida strains with only 2 h of exposure required to effectively kill 99.9% of the inoculum, and a definite synergistic effect was observed with a combination of K21 and fluconazole. EM demonstrated the presence of two forms of extracellular vesicles indicative of biofilm formation and cell lysis. Conclusion: The study established the efficacy of K21 as an antifungal agent and with fluconazole-resistant candidiasis on the increase, the development of K21 can provide a promising alternative to combat acquired drug resistance.